Fungal Infection Testing + Diagnostics for Human Health
Accurate Test Results Lead to Better Patient Outcomes
MiraVista Diagnostics understands the critical role we play in the health care and health science continuum. Because we take that responsibility seriously, we are committed to partnering with clinicians to consistently deliver:
- Superior clinical standards in testing accuracy and sensitivity
- Rapid response and test results
- Dedication to excellent client service and customer satisfaction
- Direct access to our infectious disease experts
- Quality assurance across our organization
- Compliance with regulatory mandates and industry best practices
- Continuous product and service improvement
Pulmonary Histoplasmosis: A Clinical Update – Published
MiraVista Diagnostics’ article “Pulmonary Histoplasmosis: A Clinical Update” has been published in “Journal of Fungi” as part of the Special Issue “Diagnosis and Treatment of Invasive Pulmonary Fungal Infections.” Read the article. View the PDF.
Diagnosis of Histoplasmosis Using the MVista Histoplasma Galactomannan Antigen Qualitative Lateral Flow–Based Immunoassay: A Multicenter Study.
The second US based multicenter study found high concordance with the MiraVista LFA and EIA and reported higher sensitivity with the EIA. Read more about the US LFA Multicenter Study.
Validation and Concordance Analysis of a New Lateral Flow Assay for Detection of Histoplasma Antigen in Urine
Several studies have recently been published, evaluated the MVista® CE marked Histoplasma urine antigen lateral flow immunoassay. The first study was conducted in Columbia in partnership with the CDC and reported high sensitivity with the MVD LFA. Read more about…
READ MORE →
MiraVista Institutional Biosafety Committee (IBC) Announcement
In compliance with NIAID/NIH guidelines research at MiraVista Diagnostics utilizing synthetic or recombinant DNA is annually reviewed by the MiraVista Institutional Biosafety Committee (IBC). The IBC is made up of internal and external subject matter experts to ensure that MiraVista…
READ MORE →
Test Report Updates for 2021
In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our referral testing customers. Beginning March 1, 2021 MiraVista Diagnostics will transition to an improved MVista® Histoplasma Antigen Quantitative EIA. The new…
READ MORE →
Are You Underdiagnosing Coccidioidomycosis?
Are You Underdiagnosing Coccidioidomycosis? Capture Additional Cases with Combined Antigen and Antibody Testing. Dear Colleagues, The prevailing method for diagnosis of coccidioidomycosis is serum antibody testing by immunodiffusion (ID) with a sensitivity of 84.2% and specificity of 96.5%, but a…
READ MORE →
